Gelteq Ltd., an Australian public limited company focused on clinical and science-based developments, has released its financial results for the six months ended December 31, 2024. The company has emphasized a substantial advertising budget for the financial year ending June 30, 2026, aimed at introducing its business, products, and services to potential licensees. This initiative will involve increased sales staff, participation in relevant exhibitions and conferences, and traditional online advertising and marketing efforts. Additionally, Gelteq plans to launch a series of mini websites to educate and serve as resource materials for existing and potential customers, potentially increasing sales and initiating more targeted marketing activities. The company has also indicated that if sales volumes or growth opportunities are lower than expected, it may need to explore additional financing options to continue its growth and achieve positive cash flow. Gelteq intends to adjust expenses in line with revenue to maintain financial solvency. The company's outlook remains contingent on its ability to generate sufficient sales and revenue growth.